, Moffitt Cancer Center. At the NCCN 2022 Annual Conference, Dr. Craig presented pharmacogenetic considerations and related recommendations for the treatment and supportive care of patients with cancer. Defining Pharmacogenetics Pharmacogenetics is
Search Results
Presenter: David S. Craig
Michaela J. Higgins, James M. Rae, David A. Flockhart, Daniel F. Hayes, and Vered Stearns
This work was supported in part by a Pharmacogenetics Research Network Grant # U-01 GM61373 (DAF) and by the Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale™ (DFH). References 1 Early Breast Cancer
Robert W. Carlson, Jonathan K. Larsen, Joan McClure, C. Lyn Fitzgerald, Alan P. Venook, Al B. Benson III, and Benjamin O. Anderson
, predictive biomarker expression, and pharmacogenetics exist across ethnic and racial groups, and therefore across geographic locations. Cultural and societal expectations and requirements may also require modification of the NCCN Guidelines for use outside of
events of BRAFi and MEKi in combination in patients with DTC. To evaluate the impact of experimental drugs on the serum tumor marker thyroglobulin and its correlation with overall response rate. To understand the pharmacokinetics, pharmacogenetics
patients with DTC Evaluate impact of experimental drugs on serum tumor marker thyroglobulin and its correlation with overall response rate Understand pharmacokinetics, pharmacogenetics, and pharmacodynamics of experimental drugs using serial tumor
Daniel L. Hertz and Vaibhav Sahai
%) variant carriers who were inadvertently treated with standard doses. Based on these prospective studies, dosing guidelines from the Clinical Pharmacogenetics Implementation Consortium recommend carriers of these 4 DPYD polymorphisms receive an initial 50
Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara
. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis . Cancer Res 2000 ; 60 : 6921 – 6926 . 26 Innocenti F Undevia SD Iyer L . UGT1A1*28 polymorphism is a predictor of neutropenia in irinotecan
Cho Y. Lam, Jennifer A. Minnix, Jason D. Robinson, and Paul M. Cinciripini
: 256 – 258 . 26. Johnstone EC Yudkin PL Hey K . Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch . Pharmacogenetics 2004 ; 14 : 83 – 90 . 27. Yudkin P Munafo M Hey K . Effectiveness
Mohammad Abu Zaid, Wambui G. Gathirua-Mwangi, Chunkit Fung, Patrick O. Monahan, Omar El-Charif, Annalynn M. Williams, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C. Dinh Jr, Howard D. Sesso, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group
. Late cardiovascular toxicity following chemotherapy for germ cell tumors . J Natl Compr Canc Netw 2012 ; 10 : 537 – 544 . 65. Makridakis NM di Salle E Reichardt JK . Biochemical and pharmacogenetic dissection of human steroid 5 alpha
Amit Mahipal, Minsig Choi, and Richard Kim
.727–1.337), perhaps suggesting differences in pharmacogenetics between populations. In the experimental arm, higher incidences of grade 3/4 neutropenia (41%), leucopenia (17%), hypertension (14%), abdominal pain (6%), and fatigue (12%) were reported. Other Targeted
